Publications by authors named "Sarah Ngan"
Article Synopsis
- This study investigates the impact of pathological lymph node (LN) regression after neoadjuvant chemotherapy on survival rates in patients with esophageal adenocarcinoma, addressing a gap in existing research and defining LN response classifications.
- Conducted across five UK centers, the study analyzed 17,930 LNs from 763 patients, assigning scores based on the extent of residual tumor found in the nodes after treatment, with survival outcomes assessed using advanced statistical methods.
- Results showed that patients with complete or partial LN response had significantly lower mortality rates compared to those with poor or no LN response, highlighting LN regression as a vital prognostic factor that should be considered alongside traditional staging methods.
Background: Data on the natural course of patients with breast cancer and schizophrenia are limited. Although there have been studies in assessing the incidence of breast cancer in the setting of schizophrenia, there is very little information concerning the clinical profile of these women.
Methods: We analyzed the data from our electronic notes system by searching for the terms 'schizophrenia' or 'schizophrenic' and 'breast cancer' or 'tumour' between 1993 and 2009.
Introduction: Median survival from metastatic breast cancer is 12 months without treatment, but young people can survive up to 20 years with the disease, whereas in other metastatic cancers this would be considered unusual.
Methods And Outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of first-line hormonal treatment? What are the effects of second-line hormonal treatment in women who have not responded to tamoxifen? What are the effects of first-line chemotherapy? What are the effects of first-line chemotherapy in combination with a monoclonal antibody? What are the effects of second-line chemotherapy? What are the effects of treatments for bone metastases? What are the effects of treatments for spinal cord metastases? What are the effects of treatments for cerebral or choroidal metastases? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Objective: To determine the effectiveness of vitamin D therapy in patients with asymptomatic, prostate-specific antigen (PSA)-progression of prostate cancer.
Patients And Methods: Twenty-six patients with locally advanced or metastatic prostate cancer were treated with vitamin D. Vitamin D therapy was discontinued on disease progression as assessed by symptoms or serum PSA increase.
FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease.
Eur J Nucl Med Mol Imaging
April 2009
Purpose: To evaluate the role of FDG-PET/CT scanning in the management of HIV-associated multicentric Castleman's disease (MCD) a rare lymphoproliferative disorder associated with infection by human herpesvirus 8 (HHV8).
Materials And Methods: Nine patients with histologically confirmed MCD underwent fused FDG-PET/CT scans at initial MCD diagnosis (n = 3), at MCD relapse (n = 4), or during remission (n = 2). All seven patients with active MCD had markedly elevated plasma HHV8 viral loads, but the patients in remission had no HHV8 viraemia.
New treatments offer hope but await regulatory approval in the UK
View Article and Find Full Text PDFPurpose Of Review: Gestational trophoblastic neoplasia represents the malignant end of the gestational trophoblastic disease spectrum. This review updates readers on developments in the management of gestational trophoblastic neoplasia over the past few years.
Recent Findings: Progress has been made in elucidating the genetic changes that give rise to gestational trophoblastic neoplasia.